))
S2E04: Alex Harding - Biotech Investing, Entrepreneurship and Drug Pricing
Manage episode 313065883 series 3257692
محتوای ارائه شده توسط Sharif Vakili. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط Sharif Vakili یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Is it possible for market competition to lower drug prices in pharma, or are we resigned to ever-increasing prices with each new biotech innovation? Dr. Alex Harding, biotech venture capitalist at Atlas Ventures, VP of Business Development and Corporate Strategy at Remix Therapeutics and MGH internal medicine physician, joins for a multifaceted conversation around drug pricing, being a practicing physician in biotech VC, and life sciences entrepreneurship. A contributor to the biotech newsletter the Timmerman Report, Alex discusses his recent report on the disruptive drug discovery startup, EQRx, that is contending to radically lower drug prices. Join for a thought-provoking conversation around the consequences of EQRx’s business model and the challenges with market-based drug pricing reform in the United States.
This episode marks the end of the summer interseason. The Doctor is Out will be back in a few months after a short break.
36 قسمت
اشتراک گذاری
